Resistance to antiretroviral drugs
Gómez-Cano, M.; Soriano, V.
Medicina Clinica 109(14): 546-548
1997
ISSN/ISBN: 0025-7753 PMID: 9508616 Document Number: 482209
Document emailed within 1 workday
Related Documents
Rosina, M. 2001: Resistance to antiretroviral drugs Recenti Progressi in Medicina 92(9): 546-551Calvez, V. 1998: Resistance to antiretroviral drugs Antiviral Therapy 3 Suppl. 4: 5-7
Hamers, R.L.; Derdelinckx, I.; van Vugt, M.èl.; Stevens, W.; Rinke de Wit, T.F.; Schuurman, R. 2008: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa Antiviral Therapy 13(5): 625-639
Hamers, R.L.; Derdelinckx, I.; van Vugt, M.èl.; Stevens, W.; Rinke de Wit, T.F.; Schuurman, R. 2008: The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa Antiviral Therapy 13(5): 625-639
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Vergne, L.; Malonga-Mouellet, G.; Mistoul, I.; Mavoungou, R.; Mansaray, H.; Peeters, M.; Delaporte, E. 2002: Resistance to antiretroviral treatment in Gabon: need for implementation of guidelines on antiretroviral therapy use and HIV-1 drug resistance monitoring in developing countries Journal of Acquired Immune Deficiency Syndromes 29(2): 165-168
Zapiola, I.és.; Cecchini, D.; Fernández Giuliano, S.; Martínez, M.; Rodríguez, C.; Bouzas, M.ía.B.én. 2016: HIV-1 resistance to antiretroviral drugs in pregnant women from Buenos Aires metropolitan area Medicina 76(6): 349-354
Castelbranco, E.P.íc.A.é F.él.; da Silva Souza, E.; Cavalcanti, A.M.S.; Martins, A.él.N.; de Alencar, L.C.úd.A.; Tanuri, A. 2010: Frequency of primary resistance to antiretroviral drugs and genetic variability of HIV-1 among infected pregnant women recently diagnosed in Luanda-Angola Aids Research and Human Retroviruses 26(12): 1313-1316
Gupta, R.K.; Wainberg, M.A.; Brun-Vezinet, F.; Gatell, J.M.; Albert, J.; Sönnerborg, A.; Nachega, J.B. 2013: Oral antiretroviral drugs as public health tools for HIV prevention: global implications for adherence, drug resistance, and the success of HIV treatment programs Journal of Infectious Diseases 207 Suppl. 2: S101-S106
Muhamadi, L.; Nsabagasani, X.; Tumwesigye, M.Nazarius.; Wabwire-Mangen, F.; Ekström, A-Mia.; Peterson, S.; Pariyo, G. 2010: Inadequate pre-antiretroviral care, stock-out of antiretroviral drugs and stigma: policy challenges/bottlenecks to the new WHO recommendations for earlier initiation of antiretroviral therapy (CD<350 cells/microL) in eastern Uganda Health Policy 97(2-3): 187-194
Baesi, K.; Ravanshad, M.; Ghanbarisafari, M.; Saberfar, E.; Seyedalinaghi, S.; Volk, J.E. 2014: Antiretroviral drug resistance among antiretroviral-naïve and treatment experienced patients infected with HIV in Iran Journal of Medical Virology 86(7): 1093-1098
Corzillius, M.; Mühlberger, N.; Sroczynski, G.; Jaeger, H.; Wasem, J.ür.; Siebert, U. 2004: Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV Antiviral Therapy 9(1): 27-36
Hamers, R.L.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Conradie, F.; Botes, M.E.; Wellington, M.; Osibogun, A.; Sigaloff, K.C.E.; Nankya, I.; Schuurman, R.; Wit, F.W.; Stevens, W.S.; van Vugt, Mèle.; de Wit, T.F.Rinke.; Mandaliya, K.; Abdallah, S.; Jao, I.; Dolan, M.; Schuurman, R.; Wensing, A.M.; Hamers, R.L.; Sigaloff, K.C.E.; Straatsma, E.; Wit, F.W.; van Vugt, M.; Lange, J.M.; Rinke de Wit, T.F.; Osibogun, A.; Akanmu, S.; Botes, M.E.; Conradie, F.; Ive, P.; Sanne, I.; Wallis, C.L.; Letsoalo, E.; Stevens, W.S.; Hardman, M.; Kityo, C.; Namayanja, G.; Nakatudde, L.; Nankya, I.; Kiconco, M.; Abwola, M.; Mugyenyi, P.; Ndembi, N.; Lyagoba, F.; Kaleebu 2011: HIV-1 drug resistance in antiretroviral-naive individuals in sub-Saharan Africa after rollout of antiretroviral therapy: a multicentre observational study Lancet. Infectious Diseases 11(10): 750-759
Diouf, A.; Youbong, T.J.; Maynart, M.; Ndoye, M.; Diéye, F.L.; Ndiaye, N.A.; Koita-Fall, M.B.; Ndiaye, B.; Seydi, M. 2017: Non-antiretroviral drugs uses among HIV-infected persons receiving antiretroviral therapy in Senegal: Costs and factors associated with prescription Revue d'Epidemiologie et de Sante Publique 65(4): 295-300
Newman, H.; Breunig, L.; van Zyl, G.; Stich, A.; Preiser, W. 2014: A qualitative PCR minipool strategy to screen for virologic failure and antiretroviral drug resistance in South African patients on first-line antiretroviral therapy Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology 60(4): 387-391
Wendo, C. 2003: Africans advocate antiretroviral strategy similar to DOTS. AIDS experts suggest community health workers should help in the delivery of antiretroviral drugs Lancet 362(9391): 1210
Baba, H. 1994: Studies on the problems of resistance to antituberculous drugs. II--1. Clinically applicable criteria of drug-resistance to rifampicin Kekkaku: 69(6): 387-396
Hamers, R.L.; Schuurman, R.; Sigaloff, K.C.E.; Wallis, C.L.; Kityo, C.; Siwale, M.; Mandaliya, K.; Ive, P.; Botes, M.E.; Wellington, M.; Osibogun, A.; Wit, F.W.; van Vugt, M.èl.; Stevens, W.S.; de Wit, T.F.R. 2012: Effect of pretreatment HIV-1 drug resistance on immunological, virological, and drug-resistance outcomes of first-line antiretroviral treatment in sub-Saharan Africa: a multicentre cohort study LANCET. Infectious Diseases 12(4): 307-317
Idemyor, V. 2001: HIV resistance and tolerability issues in antiretroviral therapy Journal of the National Medical Association 93(4): 151-153
Richman, D.D. 2012: Antiretroviral drug resistance in resource-limited settings Lancet 380(9849): 1210-1211